Another successful EORTC rare tumour trial: latest CATNON results presented at ASCO
Results from an EORTC trial presented at ASCO 2019 in [...]
EORTC abstracts selected at ESMO 2019
In total, EORTC will be presenting 3 abstracts (2 oral [...]
EORTC brings together experts from medical societies to compile a consensus definition for synchronous oligometastatic non small cell lung cancer
A consensus report1 was published in the Journal of Thoracic [...]
EORTC driving the policy agenda for clinical cancer research in Europe
ECCO Cancer Summit on European Cancer Care across Borders will [...]
PRESS RELEASE: EORTC and ESTRO announce E2-RADIatE platform’s first site activation for Oligometastatic Disease
Brussels, Belgium: European Organisation for Research and Treatment of Cancer [...]
EORTC at ISCB 40, Annual Conference of the International Society for Clinical Biostatistics
EORTC biostatisticians will present a number of abstracts at the [...]
Defining the best treatment for locally advanced cervical cancer
Chicago, USA: Locally advanced cervical carcinoma (where the cancer has [...]
Assessment of a potential new treatment option for patients with metastatic gastrointestinal stromal tumor (GIST) that may overcome resistance to established compounds GalleryAssessment of a potential new treatment option for patients with metastatic gastrointestinal stromal tumor (GIST) that may overcome resistance to established compounds
Assessment of a potential new treatment option for patients with metastatic gastrointestinal stromal tumor (GIST) that may overcome resistance to established compounds
At the ASCO Annual Meeting in Chicago an EORTC study [...]
Looking for answers in the search for the best treatment of retroperitoneal sarcoma
Chicago, USA: Retroperitoneal sarcoma is a malignancy where tumours develop [...]
Sustained long term survival benefit with adjuvant ipilimumab in patients with high risk stage III melanoma
Chicago, USA: Long term follow up results from the EORTC [...]
